Unresectable Malignant Solid Neoplasm Recruiting Phase 1 Trials for Dostarlimab (DB15627)

IndicationStatusPhase
DBCOND0110416 (Unresectable Malignant Solid Neoplasm)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04673448
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerTreatment